- Immutep (IMM) has entered a license and collaboration agreement with Laboratory Corporation of American Holdings (LabCorp)
- The companies will also collaborate to develop immuno-oncology products and services
- LabCorp is a North Carolina-based clinical lab company that operates one of the largest clinical laboratory networks in the world
- The collaboration also allows Immutep to enter the immuno-oncology diagnostics field
- Immutep is developing LAG-3-related immunotherapeutic products to treat cancer and autoimmune disease
- Company shares ended the day trading up a slight 1.96 percent for 26 cents
